Benign Prostatic Hyperplasia Surgical Devices Market Expected to Rise by a CAGR of 7.5% Over the Forecast Period (2017 – 2025) | Olympus Corporation, Boston Scientific Corporation, Medifocus Inc., KARL STORZ SE & Co. KG

Benign prostatic hyperplasia (BPH), commonly known as enlarged prostate or prostate gland enlargement, is a common condition that affects men in their forties and fifties. The enlarged prostate can also cause a number of unpleasant urinary symptoms, including a blockage of urine exiting the bladder. The disease can also cause issues with the bladder, urinary system, or kidneys. There are, however, a variety of successful treatments for prostate gland enlargement, including pharmaceutical therapy, invasive and minimally invasive procedures.
Sales of BPH treatment devices and equipment, as well as related services, make up the benign prostatic hyperplasia treatment devices and equipment market. The market covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market report is segmented into:
By product:

• Radiofrequency ablation device

• Resectoscopes urology lasers

• Prostatic stents

• Implants

By end-user:

• Hospitals

• Ambulatory surgical centres (ASC)

• Clinics

• Home

By procedure type:

• Transurethral needle ablation (TUNA)

• Transurethral resection of prostate (TURP)

• Transurethral incision of prostate (TUIP)

• Transurethral microwave thermotherapy (TUMT)

• Laser surgery others.

One of the key constraints for the BPH device and equipment industry is the adverse effects that patients experience following a BPH operation. Urinary incontinence, pain during urination, and difficulty completely emptying the bladder are some of the most frequent adverse effects of BPH surgery. Due to these adverse effects, patients with BPH do not prefer surgical operations (until they can no longer be avoided), reducing the demand for surgical procedures and, as a result, limiting the demand for equipment utilised by end users such as hospitals, clinics, and ambulatory surgery centres.
The major key players operating in the Benign Prostatic Hyperplasia surgical devices market are Olympus Corporation, Boston Scientific Corporation, Medifocus Inc., KARL STORZ SE & Co. KG, NxThera, Inc., ProArc Medical, Lisa Laser Products OHG, and Richard Wolf Gmbh.